---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-257430"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2026-06-04T20:15:49+00:00"
generated_at: "2026-06-04T20:51:26.592664+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics reports 100% parasite elimination in NHP study; Phase 2 for Chagas planned late 2026

## Summary
- 28-day AN2-502998 treatment in NHPs with chronic T. cruzi infection achieved 100% parasite elimination at human-target exposures, durable for 4 months post-treatment.
- Phase 1 FIH study (NCT07024589) in healthy volunteers showed favorable safety, no dose-limiting toxicities, and PK exposures at NHP efficacy thresholds.
- Chagas disease affects ~300k in U.S. and ~10M globally; no FDA-approved treatments for adults with chronic disease.
- Company plans to initiate Phase 2 proof-of-concept study late 2026; AN2-502998 eligible for FDA Tropical Disease Priority Review Voucher if approved.

## SEC filing metadata
- accession: 0001193125-26-257430
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2026-06-04T20:15:49+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312526257430/0001193125-26-257430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312526257430/d247428d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-257430
- JSON: https://secwatch.observer/filing/0001193125-26-257430.json
- Plain text: https://secwatch.observer/filing/0001193125-26-257430.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.